Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 7, 2010, Pages 1097-1107

  Beltrán, Caroll J ^a,b   Núñez, Lucía E ^a   Díaz Jiménez, David ^a   Farfan, Nancy ^a   Candia, Enzo ^a   Heine, Claudio ^c   López, Francisco ^c   González, María Julieta ^a   Quera, Rodrigo ^b,d   Hermoso, Marcela A ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c CLÍNICA LAS CONDES   (Chile)

^d Gastroenterology Unit   (Chile)

Author keywords

Crohn's disease; IL 33; Inflammatory bowel disease; ST2; Ulcerative colitis

Indexed keywords

INTERLEUKIN 33; MEMBRANE RECEPTOR; PROTEIN ST2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INTERLEUKINS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 77953721901     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21175     Document Type: Article

References (38)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
2. Sepulveda SE, Beltran CJ, Peralta A, et al. [Inflammatory bowel diseases: an immunological approach.] Rev Med Chil. 2008;136:367-375.
3. Beltran CJ, Candia E, Erranz B, et al. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis. Eur Cytokine Netw. 2009;20:33-38.
4. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258:301-304.
5. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-281. (Pubitemid 34001295)
6. Tajima S, Oshikawa K, Tominaga S, et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124:1206-1214.
7. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52:1458-1465.
8. Becerra A, Warke RV, de Bosch N, et al. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine. 2008;41:114-120.
9. Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 2004;30:1468-1473.
10. Tominaga S, Kuroiwa K, Tago K, et al. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun. 1999;264:14-18.
11. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-490.
12. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104:282-287.
13. Palmer G, Talabot-Ayer D, Lamacchia C, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60:738-749.
14. Kearley J, Buckland KF, Mathie SA, et al. Resolution of allergic inflammation and AHR is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med. 2009;179:772-781.
15. Mangan NE, Dasvarma A, McKenzie AN, et al. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol. 2007;37:1302-1312.
16. Chapuis J, Hot D, Hansmannel F, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry. 2009;14:1004-1016.
17. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205:339-346.
18. Leung BP, Xu D, Culshaw S, et al. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol. 2004;173:145-150. (Pubitemid 38797335)
19. Szerafin T, Niederpold T, Mangold A, et al. Secretion of soluble ST2 - possible explanation for systemic immunosuppression after heart surgery. Thorac Cardiovasc Surg. 2009;57:25-29.
20. Hayakawa H, Hayakawa M, Kume A, et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282:26369-26380.
21. Yin H, Huang BJ, Yang H, et al. Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. Biochem Biophys Res Commun. 2006;351:940-946.
22. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
23. Kuroiwa K, Arai T, Okazaki H, et al. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284:1104-1108. (Pubitemid 32917952)
24. Kumar S, Tzimas MN, Griswold DE, et al. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun. 1997;235:474-478.
25. Moulin D, Donze O, Talabot-Ayer D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007;40:216-225.
26. Colotta F, Dower SK, Sims JE, et al. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today. 1994;15:562-566.
27. Kuchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008;173:1229-1242.
28. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490-1497.
29. Ali S, Huber M, Kollewe C, et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007;104:18660-18665.
30. Iikura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971-978.
31. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol. 2007;178:5859-5870.
32. Humphreys NE, Xu D, Hepworth MR, et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol. 2008;180:2443-2449.
33. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106:9021-9026.
34. Hayakawa M, Hayakawa H, Matsuyama Y, et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun. 2009;387:218-222.
35. Talabot-Ayer D, Lamacchia C, Gabay C, et al. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420-19426.
36. Luthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31:84-98.
37. Verstege MI, te Velde AA, Hommes DW. Apoptosis as a therapeutic paradigm in inflammatory bowel diseases. Acta Gastroenterol Belg. 2006;69:406-416.
38. Figueroa CC, Quera PR, Valenzuela EJ, et al. Inflammatory bowel disease: experience of two Chilean centers. Rev Med Chile. 2005;133:1295-1304.